AwardTape · Defense awards · Perfusion Medical, Inc
Perfusion Medical, Inc: $5.3M in DoD and DHS awards
Perfusion Medical, Inc holds 6 DoD and DHS prime awards with $5.3M obligated Dec 11, 2023 to Apr 3, 2026. Largest category: Defense systems R&D at $3.8M; largest buyer: Department of the Air Force at $3.8M.
| Obligated FY2024+ | $5.3M |
|---|---|
| Awards | 6 |
| FY2024 | $3.8M |
| FY2025 | $0 |
| FY2026 to date | $1.5M |
| Lifetime obligated on these awards | $8.3M |
| Parent company (as reported) | Perfusion Medical, Inc |
| First and latest action | Dec 11, 2023 · Apr 3, 2026 |
| # | Category | Obligated FY2024+ | Awards | Share |
|---|---|---|---|---|
| 1 | Defense systems R&D | $3.8M | 4 awards | 72% |
| 2 | Health R&D | $1.5M | 2 awards | 28% |
| # | Agency | Obligated FY2024+ | Awards | Share |
|---|---|---|---|---|
| 1 | Department of the Air Force | $3.8M | 4 awards | 72% |
| 2 | Defense Health Agency | $1.5M | 2 awards | 28% |
| Award | Obligated FY2024+ | What | Agency | Category | Latest action |
|---|---|---|---|---|---|
| FA864924P0531 purchase order | $1.8M | Human clinical trial for safety of pm-208 anti-shock drug | Air Force | Defense systems R&D | Sep 25, 2025 DoD 90d |
| FA864924P0552 purchase order | $1.8M | Research and development of optimal dosing and formulation of pm-208 (peg-20k/8k) for af field use | Air Force | Defense systems R&D | Nov 18, 2025 DoD 90d |
| HT942726CE025 definitive contract | $1.5M | Ind-enabling studies of pm-208: a novel pre-hospital anti-shock therapeutic | Defense Health Agency | Health R&D | Apr 3, 2026 DoD 90d |
| FA864924P0833 purchase order | $110K | Polyethylene glycol-20k/8k (peg-20k/8k): a patented intravenous solution in uncontrolled hemorrhage | Air Force | Defense systems R&D | May 13, 2024 DoD 90d |
| FA864924P0274 purchase order | $75K | Polyethylene glycol-20k/8k: a patented intravenous solution to acute kidney injury | Air Force | Defense systems R&D | Dec 11, 2023 DoD 90d |
| HT942523C0065 definitive contract | $0 | Dha sbir direct to phase ii medical R&D contract from proposal no. h2d-0122 for "ind-enabling studies of pm-208: a novel pre-hospital anti-shock therapeutic" | Defense Health Agency | Health R&D | Jul 29, 2025 DoD 90d |
Source: USAspending.gov prime award data (FPDS), DoD and DHS contracts, orders and IDVs with any action since Oct 1, 2023. Obligated FY2024+ sums the obligations on those actions; total obligated is the award's lifetime figure. DoD contract actions publish on USAspending about 90 days after signing (DFARS PGI 204.6), so the latest DoD actions here trail the calendar by about 3 months. Data as of Oct 9, 2026.
Terminal: filters, alerts and CSV export for this company's awards.
7 days free for first-time subscribers, then $49/mo. Card required. Cancel before day 8 and you pay nothing.
Start free trial